Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sebelipase alfa - Alexion Pharmaceuticals

Drug Profile

Sebelipase alfa - Alexion Pharmaceuticals

Alternative Names: Kanuma; Lysosomal acid lipase - Synageva BioPharma; Recombinant human lysosomal acid lipase - Synageva BioPharma; Recombinant lysosomal acid lipase; rhLAL - Synageva BioPharma; rLAL; SBC-102; Sebelipase alfa rce

Latest Information Update: 26 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Synageva BioPharma
  • Developer Alexion Pharmaceuticals
  • Class Carboxylic ester hydrolases; Proteins
  • Mechanism of Action Sterol esterase replacements; Sterol esterase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Wolman disease; Cholesterol ester storage disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cholesterol ester storage disease; Wolman disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 11 Apr 2018 Efficacy and safety data from a phase II trial in Cholesterol ester storage disease presented at the The International Liver Congress 2018 (ILC-2018)
  • 06 Feb 2018 Pooled efficacy and adverse events data from the phase II/III VITAL trial and the phase II CL08 trial in Wolman disease released by Alexion Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top